Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06573593
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-25
Brief Title:
Efficacy and Safety of JAK Inhibitors in Patients With AA RWE Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata a Single-center Real-world Study
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The introduction of Janus Kinase inhibitors JAKi seems to revolutionize the field of alopecia areata AA therapeutics However the ideal JAKi is not yet settled and the real-world data are still missing To provide evidence about effectiveness and safety of different JAKi including tofacitinib baricitinib ritlecitinibabrocitinib upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice Furthermore we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None